But a starting price tells you almost nothing
In 2022, nine million Americans were prescribed Novo Nordiksks Ozempic, a number that could rise to 24 million in the next decade, according to a report by Morgan Stanley
The proportion is meaningfully smaller than the proportion experiencing GI symptoms, but it isn't zero
Many underlying issues remain untouched, including: Hormonal imbalances Insulin resistance Chronic inflammation Poor gut health Stress-related cortisol elevation Nutrient deficiencies When the medication is stopped, the body often rebounds because the root causes were never resolved
Charlotte Adams*, a 54-year-old woman, gained 30 pounds during menopause
Why Are Pharmaceutical Companies Offering This Model Now